Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?
This review briefly recapitulates the existing markers predictive of RA responsiveness to treatment, focusing on MTX alone or combined with a biologic. In addition to the demographic and clinical factors, an update is provided of the predictive biomarkers identified by large-scale gene and protein analyses that generated new insights into the ability of high-throughput analysis of biological systems to select new potential indicators. Among the large-scale analysis tools now available, pharmacogenetics and pharmacogenomics (including transcriptomic and proteomic approaches) have been shown to provide such new putative biomarkers of therapeutic responses.
Bansard
Carine
C
Inserm, Unité 905, France.
Lequerré
Thierry
T
Daveau
Maryvonne
M
Boyer
Olivier
O
Tron
Francois
F
Salier
Jean-Philippe
JP
Vittecoq
Olivier
O
Le-Loët
Xavier
X
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use*; D010597:Pharmacogenetics; D011379:Prognosis; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D015415:Biomarkers; D007155:Immunologic Factors; D008727:Methotrexate